董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kathleen Tregoning | 女 | Director | 52 | 6.46万美元 | 未持股 | 2023-08-07 |
| Ankit Mahadevia | 男 | Chairman of the Board | 44 | 423.97万美元 | 未持股 | 2023-08-07 |
| Milind Deshpande | 男 | Director | 67 | 10.96万美元 | 未持股 | 2023-08-07 |
| John C. Pottage, Jr. | -- | Director | 70 | 7.46万美元 | 未持股 | 2023-08-07 |
| Satyavrat Shukla | 男 | Chief Executive Officer, President and Director | 51 | 167.31万美元 | 未持股 | 2023-08-07 |
| Scott Jackson | 男 | Director | 58 | 7.21万美元 | 未持股 | 2023-08-07 |
| Kathleen Tregoning | 女 | Director | 52 | 未披露 | 未持股 | 2023-08-07 |
| Frank E. Thomas | 男 | Director | 53 | 8.21万美元 | 未持股 | 2023-08-07 |
| Patrick Vink | 男 | Lead Director | 60 | 8.46万美元 | 未持股 | 2023-08-07 |
| Cynthia Smith | 女 | Director | 54 | 6.46万美元 | 未持股 | 2023-08-07 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Stephen J. DiPalma | 男 | Interim Chief Financial Officer | 64 | 未披露 | 未持股 | 2023-08-07 |
| Timothy Keutzer | 男 | Chief Operating Officer | 55 | 未披露 | 未持股 | 2023-08-07 |
| Satyavrat Shukla | 男 | Chief Executive Officer, President and Director | 51 | 167.31万美元 | 未持股 | 2023-08-07 |
| Tamara Joseph | 女 | Chief Legal Officer | 60 | 162.54万美元 | 未持股 | 2023-08-07 |
| Kamal Hamed | 男 | Chief Medical Officer | 62 | 未披露 | 未持股 | 2023-08-07 |
董事简历
中英对照 | 中文 | 英文- Kathleen Tregoning
-
Kathleen Tregoning获得了斯坦福大学国际关系学士学位和the Kennedy School of Government at Harvard University的公共政策硕士学位。凯思琳在政策发展和宣传、利益相关者拓展和外部参与方面有20多年的经验。她于1993在旧金山开始她的职业生涯，后来在洛杉矶担任安徒生顾问，后来担任了政策顾问，然后任市长助理副市长在凯思琳市任职。2001，凯思琳移居D.C。华盛顿，担任美国国会的一名专业工作人员。为众议院的主席工作，途径和手段委员会，众议院能源和商业委员会，参议院预算委员会。在这些职位上，她是国会议员在医疗保险、医疗补助、处方药、疾病管理、医疗信息技术和急性后护理等广泛保健问题上的关键资源。凯瑟琳2006年加入Biogen，担任公共政策和政府事务副主席。在九年的时间里，她建立了公司第一个全球政府事务小组，以推进政策，使创新生物制药产品能够交付给患者。2015年，Kathleen被任命为Biogen公司事务高级副总裁，负责全球范围内公司政策和宣传工作、公司与员工沟通、媒体关系、产品传播和慈善/社区外展等工作。2017年2月，她被任命为现任职位。
Kathleen Tregoning received her Bachelor's degree in International Relations from Stanford University and her master's degree in Public Policy from the Kennedy School of Government at Harvard University.Kathleen has more than 20 years of experience in policy development and advocacy, stakeholder outreach, and external engagement. She began her career in 1993 with Andersen Consulting in San Francisco and later served as a Policy Advisory and then Assistant Deputy Mayor in the Office of the Mayor for the City of Los Angeles.In 2001 Kathleen moved to Washington, D.C. where she served as a professional staff member in the U.S. Congress, working for the chairmen of the House of Representatives Ways & Means Committee, the House Energy & Commerce Committee, and the Senate Budget Committee. In these positions she was a key resource for members of Congress on a wide range of health care issues, including Medicare, Medicaid, prescription drugs, disease management, health care information technology, and post-acute care.Kathleen joined Biogen in 2006 as Vice President, Public Policy & Government Affairs. Over the course of nine years, she built the company's first global government affairs team to advance policies that enable the delivery of innovative biopharmaceutical products to patients. In 2015 Kathleen was appointed Senior Vice President, Corporate Affairs at Biogen, overseeing the company's policy and advocacy engagement, corporate and employee communications, media relations, product communications and philanthropy/community outreach on a global basis.She was appointed to her present position in February 2017. - Kathleen Tregoning获得了斯坦福大学国际关系学士学位和the Kennedy School of Government at Harvard University的公共政策硕士学位。凯思琳在政策发展和宣传、利益相关者拓展和外部参与方面有20多年的经验。她于1993在旧金山开始她的职业生涯，后来在洛杉矶担任安徒生顾问，后来担任了政策顾问，然后任市长助理副市长在凯思琳市任职。2001，凯思琳移居D.C。华盛顿，担任美国国会的一名专业工作人员。为众议院的主席工作，途径和手段委员会，众议院能源和商业委员会，参议院预算委员会。在这些职位上，她是国会议员在医疗保险、医疗补助、处方药、疾病管理、医疗信息技术和急性后护理等广泛保健问题上的关键资源。凯瑟琳2006年加入Biogen，担任公共政策和政府事务副主席。在九年的时间里，她建立了公司第一个全球政府事务小组，以推进政策，使创新生物制药产品能够交付给患者。2015年，Kathleen被任命为Biogen公司事务高级副总裁，负责全球范围内公司政策和宣传工作、公司与员工沟通、媒体关系、产品传播和慈善/社区外展等工作。2017年2月，她被任命为现任职位。
- Kathleen Tregoning received her Bachelor's degree in International Relations from Stanford University and her master's degree in Public Policy from the Kennedy School of Government at Harvard University.Kathleen has more than 20 years of experience in policy development and advocacy, stakeholder outreach, and external engagement. She began her career in 1993 with Andersen Consulting in San Francisco and later served as a Policy Advisory and then Assistant Deputy Mayor in the Office of the Mayor for the City of Los Angeles.In 2001 Kathleen moved to Washington, D.C. where she served as a professional staff member in the U.S. Congress, working for the chairmen of the House of Representatives Ways & Means Committee, the House Energy & Commerce Committee, and the Senate Budget Committee. In these positions she was a key resource for members of Congress on a wide range of health care issues, including Medicare, Medicaid, prescription drugs, disease management, health care information technology, and post-acute care.Kathleen joined Biogen in 2006 as Vice President, Public Policy & Government Affairs. Over the course of nine years, she built the company's first global government affairs team to advance policies that enable the delivery of innovative biopharmaceutical products to patients. In 2015 Kathleen was appointed Senior Vice President, Corporate Affairs at Biogen, overseeing the company's policy and advocacy engagement, corporate and employee communications, media relations, product communications and philanthropy/community outreach on a global basis.She was appointed to her present position in February 2017.
- Ankit Mahadevia
-
Ankit Mahadevia自2015年3月起担任我们的首席执行官兼总裁，并自2013年9月起担任我们的董事会成员。他曾担任Atlas Venture公司（位于马萨诸塞州剑桥）的生命科学集团的风险合伙人。在此职位上，他支持成立了8家专注于新药发现平台和治疗产品的公司，包括Nimbus Therapeutics，被Lilly收购的Arteaus Therapeutics和Translate Bio（NASDAQ:TBIO）。他曾领导其中三家公司担任代理首席执行官，包括Synlogic公司（NASDAQ:SYBX）。在2008年加入Atlas Venture之前，Mahadevia博士在Arcion Therapeutics，Inc.的创始团队从事产品和业务开发。他还曾在Genentech，Inc.和Vanda PharmaceuticalsInc.担任业务开发职位。此前，他曾任职McKinsey&Company、Monitor Group的医疗保健集团。Mahadevia博士的职业生涯始于医疗保健政策，任职于美国参议院卫生、教育、劳工和养老金委员会、美国政府问责局和墨西哥社会保障研究所。他曾广泛发表创业演讲，包括在哈佛大学、哥伦比亚大学、西北大学和伯克利论坛。Mahadevia博士也一直积极参与生命科学创新政策，包括在NIH National Center for Advancing Translation Sciences的顾问委员会任职。Mahadevia博士拥有约翰霍普金斯医学院（Johns Hopkins School of Medicine）的医学博士学位，宾夕法尼亚大学沃顿商学院（Wharton School at the University of Pennsylvania）的工商管理硕士学位和西北大学（Northwestern University）的经济学和生物学学士学位。
Ankit Mahadevia,has been a member of Spero Therapeutics, Inc. Board of Directors since September 2013 and currently serves as Chairman of Spero Therapeutics, Inc. Board of Directors, a position he has held since August 2023. Dr. Mahadevia formerly served as Spero Therapeutics, Inc. Chief Executive and President from March 2015 until August 2023. He was formerly a Venture Partner in the life sciences group at Atlas Venture, located in Cambridge, Massachusetts. In that capacity, he supported the formation of eight companies focused on novel drug discovery platforms and therapeutic products, including Nimbus Therapeutics, Arteaus Therapeutics (acquired by Lilly), and Translate Bio (Nasdaq: TBIO). He led three of these companies as acting chief executive officer, including Synlogic (Nasdaq: SYBX). Prior to joining Atlas Venture in 2008, Dr. Mahadevia worked on product and business development with the founding team at Arcion Therapeutics, Inc. He has also held positions in business development both at Genentech, Inc. and at Vanda Pharmaceuticals Inc. Previously, he worked in the health care groups of McKinsey & Company and Monitor Group. Dr. Mahadevia began his career in health care policy, with roles in the U.S. Senate Health, Education, Labor, and Pensions committees, the U.S. Government Accountability Office and the Mexican Institute of Social Security. He has spoken widely on entrepreneurship, including at Harvard University, Columbia University, Northwestern University, and the Berkeley Forum. Dr. Mahadevia has also been active in the policy of life science innovation, including service on the Advisory Council at the NIH National Center for Advancing Translational Sciences. Dr. Mahadevia holds an M.D. from the Johns Hopkins School of Medicine, an M.B.A. from the Wharton School at the University of Pennsylvania and a B.A. in Economics and Biology from Northwestern University. - Ankit Mahadevia自2015年3月起担任我们的首席执行官兼总裁，并自2013年9月起担任我们的董事会成员。他曾担任Atlas Venture公司（位于马萨诸塞州剑桥）的生命科学集团的风险合伙人。在此职位上，他支持成立了8家专注于新药发现平台和治疗产品的公司，包括Nimbus Therapeutics，被Lilly收购的Arteaus Therapeutics和Translate Bio（NASDAQ:TBIO）。他曾领导其中三家公司担任代理首席执行官，包括Synlogic公司（NASDAQ:SYBX）。在2008年加入Atlas Venture之前，Mahadevia博士在Arcion Therapeutics，Inc.的创始团队从事产品和业务开发。他还曾在Genentech，Inc.和Vanda PharmaceuticalsInc.担任业务开发职位。此前，他曾任职McKinsey&Company、Monitor Group的医疗保健集团。Mahadevia博士的职业生涯始于医疗保健政策，任职于美国参议院卫生、教育、劳工和养老金委员会、美国政府问责局和墨西哥社会保障研究所。他曾广泛发表创业演讲，包括在哈佛大学、哥伦比亚大学、西北大学和伯克利论坛。Mahadevia博士也一直积极参与生命科学创新政策，包括在NIH National Center for Advancing Translation Sciences的顾问委员会任职。Mahadevia博士拥有约翰霍普金斯医学院（Johns Hopkins School of Medicine）的医学博士学位，宾夕法尼亚大学沃顿商学院（Wharton School at the University of Pennsylvania）的工商管理硕士学位和西北大学（Northwestern University）的经济学和生物学学士学位。
- Ankit Mahadevia,has been a member of Spero Therapeutics, Inc. Board of Directors since September 2013 and currently serves as Chairman of Spero Therapeutics, Inc. Board of Directors, a position he has held since August 2023. Dr. Mahadevia formerly served as Spero Therapeutics, Inc. Chief Executive and President from March 2015 until August 2023. He was formerly a Venture Partner in the life sciences group at Atlas Venture, located in Cambridge, Massachusetts. In that capacity, he supported the formation of eight companies focused on novel drug discovery platforms and therapeutic products, including Nimbus Therapeutics, Arteaus Therapeutics (acquired by Lilly), and Translate Bio (Nasdaq: TBIO). He led three of these companies as acting chief executive officer, including Synlogic (Nasdaq: SYBX). Prior to joining Atlas Venture in 2008, Dr. Mahadevia worked on product and business development with the founding team at Arcion Therapeutics, Inc. He has also held positions in business development both at Genentech, Inc. and at Vanda Pharmaceuticals Inc. Previously, he worked in the health care groups of McKinsey & Company and Monitor Group. Dr. Mahadevia began his career in health care policy, with roles in the U.S. Senate Health, Education, Labor, and Pensions committees, the U.S. Government Accountability Office and the Mexican Institute of Social Security. He has spoken widely on entrepreneurship, including at Harvard University, Columbia University, Northwestern University, and the Berkeley Forum. Dr. Mahadevia has also been active in the policy of life science innovation, including service on the Advisory Council at the NIH National Center for Advancing Translational Sciences. Dr. Mahadevia holds an M.D. from the Johns Hopkins School of Medicine, an M.B.A. from the Wharton School at the University of Pennsylvania and a B.A. in Economics and Biology from Northwestern University.
- Milind Deshpande
-
Milind Deshpande自2014年1月以来一直担任我们的董事会成员，目前担任董事会主席。Deshpande博士自2019年2月起担任Nayan Therapeutics的总裁兼首席执行官，自2020年1月起担任Avilar Therapeutics的总裁兼首席执行官。他也是RA Capital的风险合伙人，自2018年10月以来一直在该公司任职。Deshpande博士于2001年9月加入AchillionPharmaceuticals，Inc.，担任化学Vice President。2002年4月被任命为药物发现主管，2002年12月被任命为药物发现高级副总裁，2004年12月被任命为高级副总裁兼首席科学官，2007年6月被任命为研究执行Vice President兼首席科学官。他于2010年10月被提升为研究与开发总裁。2013年5月，Deshpande博士被任命为Achillion的总裁兼首席执行官，并加入其董事会，一直任职到2018年5月。加入Achillion公司之前，他曾担任Bristol-Myers Squibb Co.的制药研究所的铅发现和早期发现化学副董事（从1991年到2001年），在那里他曾管理新的临床候选药物的识别，以治疗传染病和神经系统疾病。从1988年到1991年，他曾担任Boston University Medical School的教员职务。Deshpande博士在印度接受本科教育后，在俄亥俄大学（Ohio University）获得有机化学博士学位。
Milind Deshpande,has served on Spero Therapeutics, Inc. Board of Directors since January 2014 and previously served as Chairman of Spero Therapeutics, Inc. Board of Directors from January 2014 to August 2023. Dr. Deshpande is the President and Chief Executive Officer at Nayan Therapeutics since February 2019, and previously served as President and Chief Executive Officer of Avilar Therapeutics from January 2020 to June 2021. He is also a Venture Partner at RA Capital, where he has served since October 2018. Dr. Deshpande served as President and Chief Executive Officer of Achillion Pharmaceuticals, Inc. and served on the board of directors from May 2013 until May 2018. He joined Achillion in September 2001 as Vice President of Chemistry, was named Head of Drug Discovery in April 2002, Senior Vice President of Drug Discovery in December 2002, Senior Vice President and Chief Scientific Officer in December 2004, Executive Vice President of Research and Chief Scientific Officer in June 2007 and President of Research and Development in October 2010. Prior to joining Achillion, Dr. Deshpande was Associate Director of Lead Discovery and Early Discovery Chemistry at the Pharmaceutical Research Institute at Bristol-Myers Squibb Co. from 1991 to 2001, where he managed the identification of new clinical candidates to treat infectious and neurological diseases. From 1988 to 1991, he held a faculty position at Boston University Medical School. Dr. Deshpande currently serves as the chairman of the board of directors of Avilar Therapeutics and as a member of the board of directors of Triana Biomedicines and Clear Creek Bio. Dr. Deshpande received his Ph.D. in Organic Chemistry from Ohio University, following his undergraduate education in India. - Milind Deshpande自2014年1月以来一直担任我们的董事会成员，目前担任董事会主席。Deshpande博士自2019年2月起担任Nayan Therapeutics的总裁兼首席执行官，自2020年1月起担任Avilar Therapeutics的总裁兼首席执行官。他也是RA Capital的风险合伙人，自2018年10月以来一直在该公司任职。Deshpande博士于2001年9月加入AchillionPharmaceuticals，Inc.，担任化学Vice President。2002年4月被任命为药物发现主管，2002年12月被任命为药物发现高级副总裁，2004年12月被任命为高级副总裁兼首席科学官，2007年6月被任命为研究执行Vice President兼首席科学官。他于2010年10月被提升为研究与开发总裁。2013年5月，Deshpande博士被任命为Achillion的总裁兼首席执行官，并加入其董事会，一直任职到2018年5月。加入Achillion公司之前，他曾担任Bristol-Myers Squibb Co.的制药研究所的铅发现和早期发现化学副董事（从1991年到2001年），在那里他曾管理新的临床候选药物的识别，以治疗传染病和神经系统疾病。从1988年到1991年，他曾担任Boston University Medical School的教员职务。Deshpande博士在印度接受本科教育后，在俄亥俄大学（Ohio University）获得有机化学博士学位。
- Milind Deshpande,has served on Spero Therapeutics, Inc. Board of Directors since January 2014 and previously served as Chairman of Spero Therapeutics, Inc. Board of Directors from January 2014 to August 2023. Dr. Deshpande is the President and Chief Executive Officer at Nayan Therapeutics since February 2019, and previously served as President and Chief Executive Officer of Avilar Therapeutics from January 2020 to June 2021. He is also a Venture Partner at RA Capital, where he has served since October 2018. Dr. Deshpande served as President and Chief Executive Officer of Achillion Pharmaceuticals, Inc. and served on the board of directors from May 2013 until May 2018. He joined Achillion in September 2001 as Vice President of Chemistry, was named Head of Drug Discovery in April 2002, Senior Vice President of Drug Discovery in December 2002, Senior Vice President and Chief Scientific Officer in December 2004, Executive Vice President of Research and Chief Scientific Officer in June 2007 and President of Research and Development in October 2010. Prior to joining Achillion, Dr. Deshpande was Associate Director of Lead Discovery and Early Discovery Chemistry at the Pharmaceutical Research Institute at Bristol-Myers Squibb Co. from 1991 to 2001, where he managed the identification of new clinical candidates to treat infectious and neurological diseases. From 1988 to 1991, he held a faculty position at Boston University Medical School. Dr. Deshpande currently serves as the chairman of the board of directors of Avilar Therapeutics and as a member of the board of directors of Triana Biomedicines and Clear Creek Bio. Dr. Deshpande received his Ph.D. in Organic Chemistry from Ohio University, following his undergraduate education in India.
- John C. Pottage, Jr.
-
JohnC.Pottage，Jr.自2018年9月以来一直担任我们的董事会成员。Pottage博士于2009年11月至2019年10月担任ViiV梦百合的高级副总裁兼首席科学和医疗官。Pottage博士从2008年9月到2009年11月担任高级副总裁，传染病医学发展中心主任，从2007年6月到2008年9月担任葛兰素史克全球抗病毒药物临床开发Vice President。在加入葛兰素史克之前，Pottage博士从2002年5月到2007年5月担任Achillion Pharmaceuticals的首席医疗官兼药物开发高级副总裁。Pottage从1998年7月到2002年5月担任Vertex Pharmaceuticals医疗主管。
John C. Pottage, Jr.,has served on Spero Therapeutics, Inc. Board of Directors since September 2018. Dr. Pottage served as Senior Vice President and Chief Scientific and Medical Officer of ViiV Healthcare from November 2009 to October 2019. From September 2008 to November 2009, Dr. Pottage served as Senior Vice President, Head of Infectious Disease Medicine Development Center and, from June 2007 to September 2008, as the Vice President, Global Clinical Development of Antivirals, at GlaxoSmithKline. Prior to joining GlaxoSmithKline, Dr. Pottage served as Chief Medical Officer and Senior Vice President of Drug Development of Achillion Pharmaceuticals from May 2002 to May 2007. From July 1998 to May 2002, Dr. Pottage served as Medical Director of Vertex Pharmaceuticals (Nasdaq: VRTX) ("Vertex"). Dr. Pottage currently serves on the board of directors of Pardes Biosciences. - JohnC.Pottage，Jr.自2018年9月以来一直担任我们的董事会成员。Pottage博士于2009年11月至2019年10月担任ViiV梦百合的高级副总裁兼首席科学和医疗官。Pottage博士从2008年9月到2009年11月担任高级副总裁，传染病医学发展中心主任，从2007年6月到2008年9月担任葛兰素史克全球抗病毒药物临床开发Vice President。在加入葛兰素史克之前，Pottage博士从2002年5月到2007年5月担任Achillion Pharmaceuticals的首席医疗官兼药物开发高级副总裁。Pottage从1998年7月到2002年5月担任Vertex Pharmaceuticals医疗主管。
- John C. Pottage, Jr.,has served on Spero Therapeutics, Inc. Board of Directors since September 2018. Dr. Pottage served as Senior Vice President and Chief Scientific and Medical Officer of ViiV Healthcare from November 2009 to October 2019. From September 2008 to November 2009, Dr. Pottage served as Senior Vice President, Head of Infectious Disease Medicine Development Center and, from June 2007 to September 2008, as the Vice President, Global Clinical Development of Antivirals, at GlaxoSmithKline. Prior to joining GlaxoSmithKline, Dr. Pottage served as Chief Medical Officer and Senior Vice President of Drug Development of Achillion Pharmaceuticals from May 2002 to May 2007. From July 1998 to May 2002, Dr. Pottage served as Medical Director of Vertex Pharmaceuticals (Nasdaq: VRTX) ("Vertex"). Dr. Pottage currently serves on the board of directors of Pardes Biosciences.
- Satyavrat Shukla
-
Satyavrat Shukla自2019年7月起担任我们的首席财务官。在加入我们之前，舒克拉先生于2012年7月至2019年7月在Vertex Pharmaceuticals担任领导职务，最近担任Vice President兼公司财务主管，领导Vertex的长期规划，年度预算和投资者关系分析流程。任职Vertex公司之前，他曾担任Cornerstone Research公司（经济和金融分析公司）的负责人，在那里他曾领导大型多学科团队，提供咨询服务，涉及金融建模、产品线和业务评估，以及为生命科学客户评估运营和金融战略和绩效。任职Cornerstone公司之前，他曾任职金融咨询公司LECG and Putnam and Hayes&Bartlett。Shukla先生在哈佛大学（Harvard University）获得经济学学士学位，并在耶鲁大学（Yale University）获得金融与战略工商管理硕士学位。他还持有特许金融分析师称号。
Satyavrat Shukla,has served as Spero Therapeutics, Inc. Chief Executive Officer and President since August 2023 and has been a member of Spero Therapeutics, Inc. Board of Directors since August 2023. He formerly served as Spero Therapeutics, Inc. Chief Financial Officer and Treasurer from January 2021 to August 2023. He has over 20 years of strategic and financial leadership experience. He was most recently Chief Financial Officer at Ziopharm Oncology, Inc. from July 2019 to December 2020, where he directed all of Ziopharm's financial aspects, including financial planning, analysis and reporting, treasury and tax functions, capital strategy and investor relations. Prior to Ziopharm, Mr. Shukla was Vice President and Global Head of Corporate Finance for Vertex Pharmaceuticals, Inc. from July 2012 to July 2019, where he managed financial planning, analysis and budgeting, and led the annual long-range planning process encompassing Vertex's entire portfolio and operations across more than 30 countries. Previously, Mr. Shukla was a Principal at Cornerstone Research, where he led teams providing consulting services for life science clients ranging from start-ups to multi-billion-dollar corporations. Prior to Cornerstone, he worked for finance consulting firms LECG Corporation and Putnam, Hayes & Bartlett, Inc. Mr. Shukla earned a B.A. in Economics from Harvard University and an M.B.A. in Finance and Strategy from Yale University. He also holds the Chartered Financial Analyst designation. - Satyavrat Shukla自2019年7月起担任我们的首席财务官。在加入我们之前，舒克拉先生于2012年7月至2019年7月在Vertex Pharmaceuticals担任领导职务，最近担任Vice President兼公司财务主管，领导Vertex的长期规划，年度预算和投资者关系分析流程。任职Vertex公司之前，他曾担任Cornerstone Research公司（经济和金融分析公司）的负责人，在那里他曾领导大型多学科团队，提供咨询服务，涉及金融建模、产品线和业务评估，以及为生命科学客户评估运营和金融战略和绩效。任职Cornerstone公司之前，他曾任职金融咨询公司LECG and Putnam and Hayes&Bartlett。Shukla先生在哈佛大学（Harvard University）获得经济学学士学位，并在耶鲁大学（Yale University）获得金融与战略工商管理硕士学位。他还持有特许金融分析师称号。
- Satyavrat Shukla,has served as Spero Therapeutics, Inc. Chief Executive Officer and President since August 2023 and has been a member of Spero Therapeutics, Inc. Board of Directors since August 2023. He formerly served as Spero Therapeutics, Inc. Chief Financial Officer and Treasurer from January 2021 to August 2023. He has over 20 years of strategic and financial leadership experience. He was most recently Chief Financial Officer at Ziopharm Oncology, Inc. from July 2019 to December 2020, where he directed all of Ziopharm's financial aspects, including financial planning, analysis and reporting, treasury and tax functions, capital strategy and investor relations. Prior to Ziopharm, Mr. Shukla was Vice President and Global Head of Corporate Finance for Vertex Pharmaceuticals, Inc. from July 2012 to July 2019, where he managed financial planning, analysis and budgeting, and led the annual long-range planning process encompassing Vertex's entire portfolio and operations across more than 30 countries. Previously, Mr. Shukla was a Principal at Cornerstone Research, where he led teams providing consulting services for life science clients ranging from start-ups to multi-billion-dollar corporations. Prior to Cornerstone, he worked for finance consulting firms LECG Corporation and Putnam, Hayes & Bartlett, Inc. Mr. Shukla earned a B.A. in Economics from Harvard University and an M.B.A. in Finance and Strategy from Yale University. He also holds the Chartered Financial Analyst designation.
- Scott Jackson
-
Scott Jackson自2020年4月起担任我们的董事会成员。杰克逊先生曾于2008年4月至2016年7月担任CelatorPharmaceuticals，Inc.首席执行官兼董事会成员，当时该公司被Jazz Pharmaceuticals plc收购。杰克逊先生在制药和生物技术行业有着30多年的企业领导经验，在礼来公司、SmithKline Beecham PLC、Imclone Systems Incorporated、Centocor Inc.（强生公司的一个部门）担任销售、营销和商业开发方面的责任越来越大，Eximias制药公司和YM BiosciencesInc.杰克逊先生目前在Macrogenics，Inc.和Glycomimetics，Inc.的董事会任职。Jackson先生拥有费城药学院（Philadelphia College of Pharmacy and Science）的药学学士学位和圣母大学（University of Notre Dame）的工商管理硕士学位。
Scott Jackson,served as chief executive officer and as a member of the board of directors of Celator Pharmaceuticals, Inc. ("Celator"), a publicly traded biopharmaceutical company, from April 2008 until July 2016, when the company was acquired by Jazz Pharmaceuticals plc. Prior to his role as chief executive officer, Mr. Jackson served as head, commercial development at Celator from September 2007 until April 2008. Mr. Jackson has more than thirty years of corporate leadership experience in the pharmaceutical and biotechnology industry and has held positions of increasing responsibility in sales, marketing and commercial development at Eli Lilly & Company, SmithKline Beecham plc, ImClone Systems Incorporated, Centocor Inc., a division of Johnson & Johnson, Eximias Pharmaceutical Corporation and YM BioSciences Inc. Mr. Jackson has served as a member of the boards of directors of MacroGenics, Inc., a publicly traded biopharmaceutical company, since January 2017, GlycoMimetics, Inc., a publicly traded clinical-stage biotechnology company, since November 2018, and Spero Therapeutics, Inc., a publicly traded biopharmaceutical company, since April 2020. Mr. Jackson also serves on the board of directors of Philabundance, a non-profit organization addressing food insecurity in the Philadelphia region. Mr. Jackson holds a B.S. in pharmacy from the Philadelphia College of Pharmacy and Science and an M.B.A. from the University of Notre Dame. - Scott Jackson自2020年4月起担任我们的董事会成员。杰克逊先生曾于2008年4月至2016年7月担任CelatorPharmaceuticals，Inc.首席执行官兼董事会成员，当时该公司被Jazz Pharmaceuticals plc收购。杰克逊先生在制药和生物技术行业有着30多年的企业领导经验，在礼来公司、SmithKline Beecham PLC、Imclone Systems Incorporated、Centocor Inc.（强生公司的一个部门）担任销售、营销和商业开发方面的责任越来越大，Eximias制药公司和YM BiosciencesInc.杰克逊先生目前在Macrogenics，Inc.和Glycomimetics，Inc.的董事会任职。Jackson先生拥有费城药学院（Philadelphia College of Pharmacy and Science）的药学学士学位和圣母大学（University of Notre Dame）的工商管理硕士学位。
- Scott Jackson,served as chief executive officer and as a member of the board of directors of Celator Pharmaceuticals, Inc. ("Celator"), a publicly traded biopharmaceutical company, from April 2008 until July 2016, when the company was acquired by Jazz Pharmaceuticals plc. Prior to his role as chief executive officer, Mr. Jackson served as head, commercial development at Celator from September 2007 until April 2008. Mr. Jackson has more than thirty years of corporate leadership experience in the pharmaceutical and biotechnology industry and has held positions of increasing responsibility in sales, marketing and commercial development at Eli Lilly & Company, SmithKline Beecham plc, ImClone Systems Incorporated, Centocor Inc., a division of Johnson & Johnson, Eximias Pharmaceutical Corporation and YM BioSciences Inc. Mr. Jackson has served as a member of the boards of directors of MacroGenics, Inc., a publicly traded biopharmaceutical company, since January 2017, GlycoMimetics, Inc., a publicly traded clinical-stage biotechnology company, since November 2018, and Spero Therapeutics, Inc., a publicly traded biopharmaceutical company, since April 2020. Mr. Jackson also serves on the board of directors of Philabundance, a non-profit organization addressing food insecurity in the Philadelphia region. Mr. Jackson holds a B.S. in pharmacy from the Philadelphia College of Pharmacy and Science and an M.B.A. from the University of Notre Dame.
- Kathleen Tregoning
-
Kathleen Tregoning，自2021年10月起担任Spero Therapeutics, Inc.董事。Tregoning女士自2020年7月起担任Cerevel Therapeutics控股公司首席公司事务官。此前，从2017年2月至2020年3月，特雷戈宁女士在法国跨国制药公司赛诺菲公司担任对外事务执行副总裁，负责领导一个整合组织，将市场准入、沟通、公共政策、政府事务、患者倡导和企业社会责任结合在一起。在加入赛诺菲之前，Tregoning女士在跨国生物技术公司Biogen Inc.工作了十多年，先是在2006年至2015年担任公共政策和政府事务副总裁，然后在2015年12月至2017年2月担任公司事务高级副总裁。此前，特雷戈宁曾在美国国会担任专业工作人员，在参议院预算委员会、众议院能源和商业委员会以及众议院筹款委员会担任卫生政策职务。Tregoning女士的职业生涯始于Andersen Consulting，在那里她为一系列行业的客户制定业务战略和流程，后来在洛杉矶市长办公室担任负责政策和预算的助理副市长。Tregoning女士毕业于斯坦福大学，获得国际关系学士学位，并拥有哈佛大学肯尼迪政府学院公共政策硕士学位。
Kathleen Tregoning,has served on Spero Therapeutics, Inc. Board of Directors since October 2021. Ms. Tregoning has served as Chief Corporate Affairs Officer of Cerevel Therapeutics Holdings, Inc. since July 2020. Previously, from February 2017 to March 2020, Ms. Tregoning served as Executive Vice President for External Affairs at Sanofi S.A., a French multinational pharmaceutical company, where she was responsible for leading an integrated organization that brought together market access, communications, public policy, government affairs,patient advocacy and corporate social responsibility. Prior to joining Sanofi, Ms. Tregoning spent more than a decade at Biogen Inc., a multinational biotechnology company, first as Vice President, Public Policy & Government Affairs, from 2006 to 2015, and then as Senior Vice President, Corporate Affairs, from December 2015 to February 2017. Previously, Ms. Tregoning served as a professional staff member in the United States Congress, where she held health policy roles with the Senate Budget Committee, the House Energy & Commerce Committee, and the House Ways & Means Committee. Ms. Tregoning began her career with Andersen Consulting, where she developed business strategies and processes for clients in a range of industries, and later served as an Assistant Deputy Mayor for Policy & Budget in the office of the Mayor of Los Angeles. Ms. Tregoning graduated from Stanford University with a B.A. in International Relations and holds an M.A. in Public Policy from the Kennedy School of Government at Harvard University. - Kathleen Tregoning，自2021年10月起担任Spero Therapeutics, Inc.董事。Tregoning女士自2020年7月起担任Cerevel Therapeutics控股公司首席公司事务官。此前，从2017年2月至2020年3月，特雷戈宁女士在法国跨国制药公司赛诺菲公司担任对外事务执行副总裁，负责领导一个整合组织，将市场准入、沟通、公共政策、政府事务、患者倡导和企业社会责任结合在一起。在加入赛诺菲之前，Tregoning女士在跨国生物技术公司Biogen Inc.工作了十多年，先是在2006年至2015年担任公共政策和政府事务副总裁，然后在2015年12月至2017年2月担任公司事务高级副总裁。此前，特雷戈宁曾在美国国会担任专业工作人员，在参议院预算委员会、众议院能源和商业委员会以及众议院筹款委员会担任卫生政策职务。Tregoning女士的职业生涯始于Andersen Consulting，在那里她为一系列行业的客户制定业务战略和流程，后来在洛杉矶市长办公室担任负责政策和预算的助理副市长。Tregoning女士毕业于斯坦福大学，获得国际关系学士学位，并拥有哈佛大学肯尼迪政府学院公共政策硕士学位。
- Kathleen Tregoning,has served on Spero Therapeutics, Inc. Board of Directors since October 2021. Ms. Tregoning has served as Chief Corporate Affairs Officer of Cerevel Therapeutics Holdings, Inc. since July 2020. Previously, from February 2017 to March 2020, Ms. Tregoning served as Executive Vice President for External Affairs at Sanofi S.A., a French multinational pharmaceutical company, where she was responsible for leading an integrated organization that brought together market access, communications, public policy, government affairs,patient advocacy and corporate social responsibility. Prior to joining Sanofi, Ms. Tregoning spent more than a decade at Biogen Inc., a multinational biotechnology company, first as Vice President, Public Policy & Government Affairs, from 2006 to 2015, and then as Senior Vice President, Corporate Affairs, from December 2015 to February 2017. Previously, Ms. Tregoning served as a professional staff member in the United States Congress, where she held health policy roles with the Senate Budget Committee, the House Energy & Commerce Committee, and the House Ways & Means Committee. Ms. Tregoning began her career with Andersen Consulting, where she developed business strategies and processes for clients in a range of industries, and later served as an Assistant Deputy Mayor for Policy & Budget in the office of the Mayor of Los Angeles. Ms. Tregoning graduated from Stanford University with a B.A. in International Relations and holds an M.A. in Public Policy from the Kennedy School of Government at Harvard University.
- Frank E. Thomas
-
Frank E. Thomas，在2011年8月加入Spero Therapeutics, Inc.，担任Spero Therapeutics, Inc.的执行副总裁、首席财务官和财务主管，目前担任执行副总裁兼首席运营官。从2011年11月至2012年5月，他还担任临时董事长和首席执行官。在加入Spero Therapeutics, Inc.之前，从2008年10月到2011年7月，他担任Molecular Biometrics商业阶段医疗诊断公司的高级副总裁、首席运营官和首席财务官。加入Molecular Biometrics之前，从2004年4月到2008年3月，他在Critical Therapeutics公共生物制药公司任职4年， 2006年6月，他被提升为总裁兼首席执行官，2006年12月，担任高级副总裁兼首席财务官。从2006年到2008年，他担任Critical Therapeutics的董事会主席。2004年之前，他担任Esperion Therapeutics生物制药公司的首席财务官和金融投资副董事长。自2007年起，他一直担任麻萨诸塞州生物技术委员会的董事会成员。他持有安娜堡密歇根大学的商业管理学士学位。
Frank E. Thomas,has served on Spero Therapeutics, Inc. Board of Directors since July 2017. Mr. Thomas is currently President and Chief Operating Officer of Orchard Therapeutics, a development-stage biotechnology company based in the United Kingdom, where he served as Chief Financial Officer and Chief Business Officer from January 2018 to March 2020. Prior to Orchard, Mr. Thomas served as the President and Chief Operating Officer of AMAG Pharmaceuticals, Inc., a commercial-stage pharmaceutical company, which was a publicly traded company that was subsequently acquired by Covis Pharma, from April 2015 to April 2017, as AMAG's Executive Vice President and Chief Operating Officer from May 2012 through April 2015 and as Executive Vice President, Chief Financial Officer and Treasurer from August 2011 through May 2012. Prior to AMAG, he served as Senior Vice President, Chief Operating Officer and Chief Financial Officer for Molecular Biometrics, Inc., a commercial-stage medical diagnostics company, from October 2008 to July 2011. Prior to Molecular Biometrics, Mr. Thomas spent four years at Critical Therapeutics, Inc., which was a publicly traded company that subsequently merged with Cornerstone Therapeutics Inc., from April 2004 to March 2008, where he was promoted to President in June 2006 and Chief Executive Officer in December 2006 from the position of Senior Vice President and Chief Financial Officer. He also served on the board of directors of Critical Therapeutics from 2006 to 2008. Prior to 2004, Mr. Thomas served as the Chief Financial Officer and Vice President of Finance and Investor Relations at Esperion Therapeutics, Inc., a public biopharmaceutical company (Nasdaq: ESPR). Mr. Thomas was a member of the board of directors of the Massachusetts Biotechnology Council from 2007 to 2015. Mr. Thomas currently serves as a member of the board of directors of Larimar Therapeutics Inc (Nasdaq: LRMR). Mr. Thomas holds a B.B.A. from the University of Michigan, Ann Arbor. - Frank E. Thomas，在2011年8月加入Spero Therapeutics, Inc.，担任Spero Therapeutics, Inc.的执行副总裁、首席财务官和财务主管，目前担任执行副总裁兼首席运营官。从2011年11月至2012年5月，他还担任临时董事长和首席执行官。在加入Spero Therapeutics, Inc.之前，从2008年10月到2011年7月，他担任Molecular Biometrics商业阶段医疗诊断公司的高级副总裁、首席运营官和首席财务官。加入Molecular Biometrics之前，从2004年4月到2008年3月，他在Critical Therapeutics公共生物制药公司任职4年， 2006年6月，他被提升为总裁兼首席执行官，2006年12月，担任高级副总裁兼首席财务官。从2006年到2008年，他担任Critical Therapeutics的董事会主席。2004年之前，他担任Esperion Therapeutics生物制药公司的首席财务官和金融投资副董事长。自2007年起，他一直担任麻萨诸塞州生物技术委员会的董事会成员。他持有安娜堡密歇根大学的商业管理学士学位。
- Frank E. Thomas,has served on Spero Therapeutics, Inc. Board of Directors since July 2017. Mr. Thomas is currently President and Chief Operating Officer of Orchard Therapeutics, a development-stage biotechnology company based in the United Kingdom, where he served as Chief Financial Officer and Chief Business Officer from January 2018 to March 2020. Prior to Orchard, Mr. Thomas served as the President and Chief Operating Officer of AMAG Pharmaceuticals, Inc., a commercial-stage pharmaceutical company, which was a publicly traded company that was subsequently acquired by Covis Pharma, from April 2015 to April 2017, as AMAG's Executive Vice President and Chief Operating Officer from May 2012 through April 2015 and as Executive Vice President, Chief Financial Officer and Treasurer from August 2011 through May 2012. Prior to AMAG, he served as Senior Vice President, Chief Operating Officer and Chief Financial Officer for Molecular Biometrics, Inc., a commercial-stage medical diagnostics company, from October 2008 to July 2011. Prior to Molecular Biometrics, Mr. Thomas spent four years at Critical Therapeutics, Inc., which was a publicly traded company that subsequently merged with Cornerstone Therapeutics Inc., from April 2004 to March 2008, where he was promoted to President in June 2006 and Chief Executive Officer in December 2006 from the position of Senior Vice President and Chief Financial Officer. He also served on the board of directors of Critical Therapeutics from 2006 to 2008. Prior to 2004, Mr. Thomas served as the Chief Financial Officer and Vice President of Finance and Investor Relations at Esperion Therapeutics, Inc., a public biopharmaceutical company (Nasdaq: ESPR). Mr. Thomas was a member of the board of directors of the Massachusetts Biotechnology Council from 2007 to 2015. Mr. Thomas currently serves as a member of the board of directors of Larimar Therapeutics Inc (Nasdaq: LRMR). Mr. Thomas holds a B.B.A. from the University of Michigan, Ann Arbor.
- Patrick Vink
-
Patrick Vink，2012年9月开始，他就是高级业务部的总经理和高级副总裁。在这之前，他是迈兰公司，（一家由他协调公司所有上市业务的上市制药公司）的医院业务全球主管和生物制品的全球主管和高级副总裁。2008年他加入迈兰，建立了瑞士的公司业务，这是一些全球功能的基础。在加入迈兰前，他在制药公司担任领导职位，包括山德士商业特效经营商业制药公司，诺华制药公司的分部的领导。诺华公司是一家上市全球制药公司。他是Biogen公司的欧洲中部和国际销售副总裁，他是赛诺菲圣德拉堡，（一家全球保健公司）的心血管和血栓形成的全球市场部的董事。
Patrick Vink,has served on Spero Therapeutics, Inc. Board of Directors since September 2015 and currently serves as Spero Therapeutics, Inc. Lead Director, a position he has held since August 2023. Dr. Vink has been an advisor to the pharmaceutical industry since 2015 and board member of several companies. Previously, Dr. Vink was employed at Cubist Pharmaceuticals, Inc ("Cubist"). Most recently, he served as Executive Vice-President and Chief Operating Officer, overseeing all worldwide commercial and technical operations as well as global alliance management and managing the company's profit and loss. He joined Cubist in 2012 as Senior Vice President and Head of all International Business Operations. In this role, he was responsible for the business activities in International markets outside USA. Prior to joining Cubist, Dr. Vink served as Senior Vice President, Global Head of Hospital Business and Global Head of Biologics for Mylan Inc. In this role, Dr. Vink managed the global hospital business of the company. He joined Mylan in 2008 and established a number of global functions for the company in Switzerland. Before joining Mylan, Dr. Vink held several leadership positions across the industry, including Head of Global Business Franchise Biopharmaceuticals for Novartis Sandoz; Vice President International Business for Biogen, Inc.; and Head of Worldwide Marketing, Cardiovascular and Thrombosis for Sanofi-Synthélabo SA. Dr. Vink served as a member of the Executive Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA) between 2013 and 2015. Dr. Vink graduated as a medical doctor from the University of Leiden, Netherlands in 1988 and obtained his M.B.A. in 1992 from the University of Rochester. Dr. Vink serves on the boards of directors of Santhera Pharmaceuticals AG, Amryt Pharma PLC., and is Chairman of the board of directors of two privately held companies. - Patrick Vink，2012年9月开始，他就是高级业务部的总经理和高级副总裁。在这之前，他是迈兰公司，（一家由他协调公司所有上市业务的上市制药公司）的医院业务全球主管和生物制品的全球主管和高级副总裁。2008年他加入迈兰，建立了瑞士的公司业务，这是一些全球功能的基础。在加入迈兰前，他在制药公司担任领导职位，包括山德士商业特效经营商业制药公司，诺华制药公司的分部的领导。诺华公司是一家上市全球制药公司。他是Biogen公司的欧洲中部和国际销售副总裁，他是赛诺菲圣德拉堡，（一家全球保健公司）的心血管和血栓形成的全球市场部的董事。
- Patrick Vink,has served on Spero Therapeutics, Inc. Board of Directors since September 2015 and currently serves as Spero Therapeutics, Inc. Lead Director, a position he has held since August 2023. Dr. Vink has been an advisor to the pharmaceutical industry since 2015 and board member of several companies. Previously, Dr. Vink was employed at Cubist Pharmaceuticals, Inc ("Cubist"). Most recently, he served as Executive Vice-President and Chief Operating Officer, overseeing all worldwide commercial and technical operations as well as global alliance management and managing the company's profit and loss. He joined Cubist in 2012 as Senior Vice President and Head of all International Business Operations. In this role, he was responsible for the business activities in International markets outside USA. Prior to joining Cubist, Dr. Vink served as Senior Vice President, Global Head of Hospital Business and Global Head of Biologics for Mylan Inc. In this role, Dr. Vink managed the global hospital business of the company. He joined Mylan in 2008 and established a number of global functions for the company in Switzerland. Before joining Mylan, Dr. Vink held several leadership positions across the industry, including Head of Global Business Franchise Biopharmaceuticals for Novartis Sandoz; Vice President International Business for Biogen, Inc.; and Head of Worldwide Marketing, Cardiovascular and Thrombosis for Sanofi-Synthélabo SA. Dr. Vink served as a member of the Executive Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA) between 2013 and 2015. Dr. Vink graduated as a medical doctor from the University of Leiden, Netherlands in 1988 and obtained his M.B.A. in 1992 from the University of Rochester. Dr. Vink serves on the boards of directors of Santhera Pharmaceuticals AG, Amryt Pharma PLC., and is Chairman of the board of directors of two privately held companies.
- Cynthia Smith
-
Cynthia Smith是理学硕士和工商管理硕士，自2013年6月以来担任Spero Therapeutics, Inc.的首席商务官。从2008年10月到2013年3月她在Affymax Inc.（关注新肾疗法的开发和商业化的生物技术公司）工作，最近是市场准入和商业发展（Market Access and Commercial Development）的副总裁。从2000年7月到2008年10月她在Merck and Co., Inc.工作，在那里她担任各种管理市场、公司战略和公共事务的领导职位，最近担任医疗体系和医疗战略（Healthcare System and Medicare Strategy）的执行董事。从1995年6月到2000年7月她在克林顿政府下的白宫行政管理和预算局工作。她从北卡罗莱纳大学教堂山分校获得学士学位，从罗格斯大学伊格尔顿研究所获得公共政策硕士学位，从宾夕法尼亚大学沃顿商学院获得工商管理硕士学位。
Cynthia Smith was appointed to board of directors upon the closing of the Merger. Since January 2017, Ms. Smith has consulted as a strategic advisor for biotechnology companies. Previoly, she served as Chief Commercial Officer and a member of the Executive Committee of ZS Pharma, Inc. ("ZS Pharma"), a specialty pharmaceutical company developing therapies for treatment of hyperkalemia and liver diseases, from 2013 to 2016, where she led efforts to transition the company from a development stage company to a commercial enterprise. ZS Pharma was acquired by AstraZeneca in 2015. Prior to ZS Pharma, Ms. Smith served as Vice President, Market Access and Commercial Development at Affymax, Inc., a biopharmaceutical company, from 2008 to 2013. From 2000 to 2008, she held vario senior leadership positions in market access, corporate strategy, government relations and external affairs at Merck & Co. Before beginning her career in the biopharmaceutical indtry, Ms. Smith served as a healthcare policy analyst in the Office of Management and Budget at the White Hoe from 1995 to 2000. Ms. Smith currently serves on the boards of directors of publicly traded biotechnology companies Agios Pharmaceuticals, Inc., Akebia Therapeutics, Inc., Protara Therapeutics, Inc., and Spero Therapeutics, Inc., and on the board of directors of the French American Foundation. Ms. Smith previoly served on the board of directors of Nivalis Therapeutics, Inc. from November 2016 to July 2017 and on the board of directors of Dicerna Pharmaceuticals, Inc. from Augt 2018 until its acquisition by Novo Nordisk A/S in 2021. Ms. Smith earned a B.A. from the University of North Carolina at Chapel Hill, an M.B.A. from the Wharton School and an M.S. in public policy from the Eagleton Institute of Politics at Rutgers University. - Cynthia Smith是理学硕士和工商管理硕士，自2013年6月以来担任Spero Therapeutics, Inc.的首席商务官。从2008年10月到2013年3月她在Affymax Inc.（关注新肾疗法的开发和商业化的生物技术公司）工作，最近是市场准入和商业发展（Market Access and Commercial Development）的副总裁。从2000年7月到2008年10月她在Merck and Co., Inc.工作，在那里她担任各种管理市场、公司战略和公共事务的领导职位，最近担任医疗体系和医疗战略（Healthcare System and Medicare Strategy）的执行董事。从1995年6月到2000年7月她在克林顿政府下的白宫行政管理和预算局工作。她从北卡罗莱纳大学教堂山分校获得学士学位，从罗格斯大学伊格尔顿研究所获得公共政策硕士学位，从宾夕法尼亚大学沃顿商学院获得工商管理硕士学位。
- Cynthia Smith was appointed to board of directors upon the closing of the Merger. Since January 2017, Ms. Smith has consulted as a strategic advisor for biotechnology companies. Previoly, she served as Chief Commercial Officer and a member of the Executive Committee of ZS Pharma, Inc. ("ZS Pharma"), a specialty pharmaceutical company developing therapies for treatment of hyperkalemia and liver diseases, from 2013 to 2016, where she led efforts to transition the company from a development stage company to a commercial enterprise. ZS Pharma was acquired by AstraZeneca in 2015. Prior to ZS Pharma, Ms. Smith served as Vice President, Market Access and Commercial Development at Affymax, Inc., a biopharmaceutical company, from 2008 to 2013. From 2000 to 2008, she held vario senior leadership positions in market access, corporate strategy, government relations and external affairs at Merck & Co. Before beginning her career in the biopharmaceutical indtry, Ms. Smith served as a healthcare policy analyst in the Office of Management and Budget at the White Hoe from 1995 to 2000. Ms. Smith currently serves on the boards of directors of publicly traded biotechnology companies Agios Pharmaceuticals, Inc., Akebia Therapeutics, Inc., Protara Therapeutics, Inc., and Spero Therapeutics, Inc., and on the board of directors of the French American Foundation. Ms. Smith previoly served on the board of directors of Nivalis Therapeutics, Inc. from November 2016 to July 2017 and on the board of directors of Dicerna Pharmaceuticals, Inc. from Augt 2018 until its acquisition by Novo Nordisk A/S in 2021. Ms. Smith earned a B.A. from the University of North Carolina at Chapel Hill, an M.B.A. from the Wharton School and an M.S. in public policy from the Eagleton Institute of Politics at Rutgers University.
高管简历
中英对照 | 中文 | 英文- Stephen J. DiPalma
Stephen J. DiPalma在2015年3月成为临时首席财务官。之前，他担任两个上市公司的首席财务官，八个私营公司的首席财务官，首席运营官（COO），首席执行官或董事（除了咨询客户之外）。他参加Cambridge Biotech的成功重组，从第11章破产保护到Aquila BioPharmaceuticals，领导RXi Pharmaceuticals上市工作，在国际融资和企业结构中有着丰富的经验。他是Cognoptix Inc.的前任董事会主席，服务于Phytera, Inc.的董事会。他获得Babson College的工商管理硕士学位和the University of Massachusetts-Lowell的学士学位。
Stephen J. DiPalma,has served as Spero Therapeutics, Inc. Interim Chief Financial Officer and Treasurer since August 2023. He is a Managing Director of Danforth Advisors, LLC, a financial consultancy that specializes in working with life sciences companies. Prior to and during his tenure at Danforth, Mr. DiPalma has served as Interim Chief Financial Officer to several public and emerging companies in various stages of development, including as Spero Therapeutics, Inc. Interim Chief Financial Officer from November 2019 to January 2021. Mr. DiPalma joined Danforth in 2014 and served as Chief Financial Officer at Forum Pharmaceuticals from 2009 to 2014. He holds a B.S. from the University of Massachusetts and M.B.A. from Babson College.- Stephen J. DiPalma在2015年3月成为临时首席财务官。之前，他担任两个上市公司的首席财务官，八个私营公司的首席财务官，首席运营官（COO），首席执行官或董事（除了咨询客户之外）。他参加Cambridge Biotech的成功重组，从第11章破产保护到Aquila BioPharmaceuticals，领导RXi Pharmaceuticals上市工作，在国际融资和企业结构中有着丰富的经验。他是Cognoptix Inc.的前任董事会主席，服务于Phytera, Inc.的董事会。他获得Babson College的工商管理硕士学位和the University of Massachusetts-Lowell的学士学位。
- Stephen J. DiPalma,has served as Spero Therapeutics, Inc. Interim Chief Financial Officer and Treasurer since August 2023. He is a Managing Director of Danforth Advisors, LLC, a financial consultancy that specializes in working with life sciences companies. Prior to and during his tenure at Danforth, Mr. DiPalma has served as Interim Chief Financial Officer to several public and emerging companies in various stages of development, including as Spero Therapeutics, Inc. Interim Chief Financial Officer from November 2019 to January 2021. Mr. DiPalma joined Danforth in 2014 and served as Chief Financial Officer at Forum Pharmaceuticals from 2009 to 2014. He holds a B.S. from the University of Massachusetts and M.B.A. from Babson College.
- Timothy Keutzer
Timothy Keutzer自2019年6月起担任我们的首席开发官。他在制药行业拥有超过20年的经验，涉及多个功能和治疗领域。加入Spero之前，Keutzer曾在Cubist Pharmaceuticals担任多个职位，包括2014年5月至2015年7月担任项目和投资组合管理Vice President。在Cubist，Keutzer先生是头孢托洛赞/他唑巴坦的项目负责人，该项目从第1阶段快速发展到第3阶段，并于2014年12月获得FDA批准。在担任该职位之前，他还领导了Cubist&8217；s的几个未经许可的开发项目，并领导了Cubicin的商业供应链。Cubist之前的经验跨越多个药物类别，包括Genetics Institute的临床前PK/PD和临床运营，以及Wyeth的全球战略营销和项目管理。Tim在Contract Toxicology Labs开始他的职业生涯。Keutzer先生在肯塔基大学获得学士学位。
Timothy Keutzer,has served as Spero Therapeutics, Inc. Chief Operating Officer since February 2023 and previously served as Spero Therapeutics, Inc. Chief Development Officer from June 2019 until February 2023 and as Spero Therapeutics, Inc. Senior Vice President, Development from September 2015 to June 2019. He has over 20 years' experience in the pharmaceutical industry, spanning multiple functional and therapeutic areas. Prior to joining Spero, Mr. Keutzer served in various roles at Cubist Pharmaceuticals, including Vice President of Program and Portfolio Management from May 2014 to July 2015. At Cubist Mr. Keutzer was the program leader for ceftolozane/tazobactam, which progressed rapidly from Phase 1 to Phase 3, and was approved in the FDA in December of 2014. Prior to that role, he also led several of Cubist's inlicensed development programs, and also led the commercial supply chain for Cubicin. His experience before Cubist spans multiple drug classes and includes preclinical PK/PD and clinical operations at Genetics Institute, as well as global strategic marketing and program management at Wyeth. Tim began his career in contract toxicology labs. Mr. Keutzer earned his bachelor's degree from the University of Kentucky.- Timothy Keutzer自2019年6月起担任我们的首席开发官。他在制药行业拥有超过20年的经验，涉及多个功能和治疗领域。加入Spero之前，Keutzer曾在Cubist Pharmaceuticals担任多个职位，包括2014年5月至2015年7月担任项目和投资组合管理Vice President。在Cubist，Keutzer先生是头孢托洛赞/他唑巴坦的项目负责人，该项目从第1阶段快速发展到第3阶段，并于2014年12月获得FDA批准。在担任该职位之前，他还领导了Cubist&8217；s的几个未经许可的开发项目，并领导了Cubicin的商业供应链。Cubist之前的经验跨越多个药物类别，包括Genetics Institute的临床前PK/PD和临床运营，以及Wyeth的全球战略营销和项目管理。Tim在Contract Toxicology Labs开始他的职业生涯。Keutzer先生在肯塔基大学获得学士学位。
- Timothy Keutzer,has served as Spero Therapeutics, Inc. Chief Operating Officer since February 2023 and previously served as Spero Therapeutics, Inc. Chief Development Officer from June 2019 until February 2023 and as Spero Therapeutics, Inc. Senior Vice President, Development from September 2015 to June 2019. He has over 20 years' experience in the pharmaceutical industry, spanning multiple functional and therapeutic areas. Prior to joining Spero, Mr. Keutzer served in various roles at Cubist Pharmaceuticals, including Vice President of Program and Portfolio Management from May 2014 to July 2015. At Cubist Mr. Keutzer was the program leader for ceftolozane/tazobactam, which progressed rapidly from Phase 1 to Phase 3, and was approved in the FDA in December of 2014. Prior to that role, he also led several of Cubist's inlicensed development programs, and also led the commercial supply chain for Cubicin. His experience before Cubist spans multiple drug classes and includes preclinical PK/PD and clinical operations at Genetics Institute, as well as global strategic marketing and program management at Wyeth. Tim began his career in contract toxicology labs. Mr. Keutzer earned his bachelor's degree from the University of Kentucky.
- Satyavrat Shukla
Satyavrat Shukla自2019年7月起担任我们的首席财务官。在加入我们之前，舒克拉先生于2012年7月至2019年7月在Vertex Pharmaceuticals担任领导职务，最近担任Vice President兼公司财务主管，领导Vertex的长期规划，年度预算和投资者关系分析流程。任职Vertex公司之前，他曾担任Cornerstone Research公司（经济和金融分析公司）的负责人，在那里他曾领导大型多学科团队，提供咨询服务，涉及金融建模、产品线和业务评估，以及为生命科学客户评估运营和金融战略和绩效。任职Cornerstone公司之前，他曾任职金融咨询公司LECG and Putnam and Hayes&Bartlett。Shukla先生在哈佛大学（Harvard University）获得经济学学士学位，并在耶鲁大学（Yale University）获得金融与战略工商管理硕士学位。他还持有特许金融分析师称号。
Satyavrat Shukla,has served as Spero Therapeutics, Inc. Chief Executive Officer and President since August 2023 and has been a member of Spero Therapeutics, Inc. Board of Directors since August 2023. He formerly served as Spero Therapeutics, Inc. Chief Financial Officer and Treasurer from January 2021 to August 2023. He has over 20 years of strategic and financial leadership experience. He was most recently Chief Financial Officer at Ziopharm Oncology, Inc. from July 2019 to December 2020, where he directed all of Ziopharm's financial aspects, including financial planning, analysis and reporting, treasury and tax functions, capital strategy and investor relations. Prior to Ziopharm, Mr. Shukla was Vice President and Global Head of Corporate Finance for Vertex Pharmaceuticals, Inc. from July 2012 to July 2019, where he managed financial planning, analysis and budgeting, and led the annual long-range planning process encompassing Vertex's entire portfolio and operations across more than 30 countries. Previously, Mr. Shukla was a Principal at Cornerstone Research, where he led teams providing consulting services for life science clients ranging from start-ups to multi-billion-dollar corporations. Prior to Cornerstone, he worked for finance consulting firms LECG Corporation and Putnam, Hayes & Bartlett, Inc. Mr. Shukla earned a B.A. in Economics from Harvard University and an M.B.A. in Finance and Strategy from Yale University. He also holds the Chartered Financial Analyst designation.- Satyavrat Shukla自2019年7月起担任我们的首席财务官。在加入我们之前，舒克拉先生于2012年7月至2019年7月在Vertex Pharmaceuticals担任领导职务，最近担任Vice President兼公司财务主管，领导Vertex的长期规划，年度预算和投资者关系分析流程。任职Vertex公司之前，他曾担任Cornerstone Research公司（经济和金融分析公司）的负责人，在那里他曾领导大型多学科团队，提供咨询服务，涉及金融建模、产品线和业务评估，以及为生命科学客户评估运营和金融战略和绩效。任职Cornerstone公司之前，他曾任职金融咨询公司LECG and Putnam and Hayes&Bartlett。Shukla先生在哈佛大学（Harvard University）获得经济学学士学位，并在耶鲁大学（Yale University）获得金融与战略工商管理硕士学位。他还持有特许金融分析师称号。
- Satyavrat Shukla,has served as Spero Therapeutics, Inc. Chief Executive Officer and President since August 2023 and has been a member of Spero Therapeutics, Inc. Board of Directors since August 2023. He formerly served as Spero Therapeutics, Inc. Chief Financial Officer and Treasurer from January 2021 to August 2023. He has over 20 years of strategic and financial leadership experience. He was most recently Chief Financial Officer at Ziopharm Oncology, Inc. from July 2019 to December 2020, where he directed all of Ziopharm's financial aspects, including financial planning, analysis and reporting, treasury and tax functions, capital strategy and investor relations. Prior to Ziopharm, Mr. Shukla was Vice President and Global Head of Corporate Finance for Vertex Pharmaceuticals, Inc. from July 2012 to July 2019, where he managed financial planning, analysis and budgeting, and led the annual long-range planning process encompassing Vertex's entire portfolio and operations across more than 30 countries. Previously, Mr. Shukla was a Principal at Cornerstone Research, where he led teams providing consulting services for life science clients ranging from start-ups to multi-billion-dollar corporations. Prior to Cornerstone, he worked for finance consulting firms LECG Corporation and Putnam, Hayes & Bartlett, Inc. Mr. Shukla earned a B.A. in Economics from Harvard University and an M.B.A. in Finance and Strategy from Yale University. He also holds the Chartered Financial Analyst designation.
- Tamara Joseph
Tamara Joseph自2020年12月起担任我们的首席法律官。她在生物技术领域拥有20多年的领导职务，负责监督法律，公共和政府事务，合规和风险管理。Joseph女士最近担任MillendoTherapeutics，Inc.的总法律顾问，此前曾担任Enzyvant Therapeutics Ltd.，Invivo治疗控股公司，CubistPharmaceuticals，Inc.，Mayne Pharma Ltd.和Transkaryotic Therapies，Inc.的总法律顾问。她的经验还包括建立和领导Biogen Idec Inc.法律和公共事务部门的前美国业务。Joseph女士获得了杜克大学经济学学士学位，密歇根大学法学院法学博士学位以及比利时欧洲学院和巴黎大学的法学硕士学位。
Tamara Joseph,has served as Spero Therapeutics, Inc. Chief Legal Officer since December 2020. She has over 20 years of leadership roles in the biotechnology sector, overseeing legal, public and government affairs, compliance and risk management. Ms. Joseph most recently served as General Counsel at Millendo Therapeutics, Inc. and previously served as General Counsel at Enzyvant Therapeutics Ltd., InVivo Therapeutics Holdings Corp., Cubist Pharmaceuticals, Inc., Mayne Pharma Ltd., and Transkaryotic Therapies, Inc. Her experience also includes establishing and leading the international legal and public affairs departments of Biogen Idec Inc. Ms. Joseph received her B.A. in economics from Duke University, her J.D. from the University of Michigan Law School and her L.L.M. degrees from the College of Europe in Belgium and the University of Paris.- Tamara Joseph自2020年12月起担任我们的首席法律官。她在生物技术领域拥有20多年的领导职务，负责监督法律，公共和政府事务，合规和风险管理。Joseph女士最近担任MillendoTherapeutics，Inc.的总法律顾问，此前曾担任Enzyvant Therapeutics Ltd.，Invivo治疗控股公司，CubistPharmaceuticals，Inc.，Mayne Pharma Ltd.和Transkaryotic Therapies，Inc.的总法律顾问。她的经验还包括建立和领导Biogen Idec Inc.法律和公共事务部门的前美国业务。Joseph女士获得了杜克大学经济学学士学位，密歇根大学法学院法学博士学位以及比利时欧洲学院和巴黎大学的法学硕士学位。
- Tamara Joseph,has served as Spero Therapeutics, Inc. Chief Legal Officer since December 2020. She has over 20 years of leadership roles in the biotechnology sector, overseeing legal, public and government affairs, compliance and risk management. Ms. Joseph most recently served as General Counsel at Millendo Therapeutics, Inc. and previously served as General Counsel at Enzyvant Therapeutics Ltd., InVivo Therapeutics Holdings Corp., Cubist Pharmaceuticals, Inc., Mayne Pharma Ltd., and Transkaryotic Therapies, Inc. Her experience also includes establishing and leading the international legal and public affairs departments of Biogen Idec Inc. Ms. Joseph received her B.A. in economics from Duke University, her J.D. from the University of Michigan Law School and her L.L.M. degrees from the College of Europe in Belgium and the University of Paris.
- Kamal Hamed
Kamal Hamed，自2022年9月起担任Spero Therapeutics, Inc.首席医疗官。哈默德博士有20多年的经验领导各种抗感染临床开发项目在抗菌，抗病毒，抗疟和抗真菌。在加入Spero Therapeutics, Inc.之前，他是Roivant Sciences子公司Lysovant Sciences的首席营销官。在加入Lysovant之前，哈默德博士是Basilea Pharmaceutica的临床开发和医疗事务主管。在他职业生涯的早期，他曾在诺华（包括抗感染药物治疗领域主管）、百时美施贵宝和拜耳担任临床开发和医疗事务高级职位，领导多个抗感染产品的成功全球开发、批准和上市后医疗事务支持。在加入制药行业之前，哈默德博士作为一名学术医生工作了14年。他拥有贝鲁特美国大学的医学博士学位、约翰·霍普金斯大学的公共卫生硕士学位和南佛罗里达大学的工商管理硕士学位。哈默德博士在UMDNJ – Robert Wood Johnson医学院完成了内科住院医师实习，并在斯坦福大学医学院完成了传染病研究金。他是美国内科医师学会和美国传染病学会的研究员，在同行评议的期刊上发表了110多篇手稿。
Kamal Hamed,has served as Spero Therapeutics, Inc. Chief Medical Officer since September 2022. Dr. Hamed has over 20 years of experience leading various anti-infective clinical development programs in antibacterials, antivirals, antimalarials, and antifungals. Before joining Spero Therapeutics, Inc. , he was the CMO at Lysovant Sciences, a subsidiary of Roivant Sciences. Prior to his time at Lysovant, Dr. Hamed was Head of Clinical Development & Medical Affairs at Basilea Pharmaceutica. Earlier in his career, he held senior positions in clinical development and medical affairs at Novartis (including Therapeutic Area Head for Anti-infectives), Bristol-Myers Squibb, and Bayer, spearheading the successful global development, approval, and post-marketing medical affairs support of multiple anti-infective products. Prior to joining the pharmaceutical industry, Dr. Hamed worked as an academic physician for 14 years. He holds an M.D. degree from the American University of Beirut, an M.P.H. degree from Johns Hopkins University, and an M.B.A. degree from the University of South Florida. Dr. Hamed completed a residency in Internal Medicine at UMDNJ–Robert Wood Johnson Medical School and a fellowship in Infectious Diseases at Stanford University School of Medicine. He is a fellow of both the American College of Physicians and the Infectious Diseases Society of America and has published over 110 manuscripts in peer-reviewed journals.- Kamal Hamed，自2022年9月起担任Spero Therapeutics, Inc.首席医疗官。哈默德博士有20多年的经验领导各种抗感染临床开发项目在抗菌，抗病毒，抗疟和抗真菌。在加入Spero Therapeutics, Inc.之前，他是Roivant Sciences子公司Lysovant Sciences的首席营销官。在加入Lysovant之前，哈默德博士是Basilea Pharmaceutica的临床开发和医疗事务主管。在他职业生涯的早期，他曾在诺华（包括抗感染药物治疗领域主管）、百时美施贵宝和拜耳担任临床开发和医疗事务高级职位，领导多个抗感染产品的成功全球开发、批准和上市后医疗事务支持。在加入制药行业之前，哈默德博士作为一名学术医生工作了14年。他拥有贝鲁特美国大学的医学博士学位、约翰·霍普金斯大学的公共卫生硕士学位和南佛罗里达大学的工商管理硕士学位。哈默德博士在UMDNJ – Robert Wood Johnson医学院完成了内科住院医师实习，并在斯坦福大学医学院完成了传染病研究金。他是美国内科医师学会和美国传染病学会的研究员，在同行评议的期刊上发表了110多篇手稿。
- Kamal Hamed,has served as Spero Therapeutics, Inc. Chief Medical Officer since September 2022. Dr. Hamed has over 20 years of experience leading various anti-infective clinical development programs in antibacterials, antivirals, antimalarials, and antifungals. Before joining Spero Therapeutics, Inc. , he was the CMO at Lysovant Sciences, a subsidiary of Roivant Sciences. Prior to his time at Lysovant, Dr. Hamed was Head of Clinical Development & Medical Affairs at Basilea Pharmaceutica. Earlier in his career, he held senior positions in clinical development and medical affairs at Novartis (including Therapeutic Area Head for Anti-infectives), Bristol-Myers Squibb, and Bayer, spearheading the successful global development, approval, and post-marketing medical affairs support of multiple anti-infective products. Prior to joining the pharmaceutical industry, Dr. Hamed worked as an academic physician for 14 years. He holds an M.D. degree from the American University of Beirut, an M.P.H. degree from Johns Hopkins University, and an M.B.A. degree from the University of South Florida. Dr. Hamed completed a residency in Internal Medicine at UMDNJ–Robert Wood Johnson Medical School and a fellowship in Infectious Diseases at Stanford University School of Medicine. He is a fellow of both the American College of Physicians and the Infectious Diseases Society of America and has published over 110 manuscripts in peer-reviewed journals.